Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Ose Immunotherapeutics has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are handled by 3 distinct examiners across 3 distinct art units. The busiest examiner, Dent, Alana Harris, is managing 2 pending office actions. This distribution requires a strategy that accounts for both the individual examiner's tendencies and the broader requirements of the art units.
The presence of the 3 distinct art units suggests that the portfolio covers several specialized sub-sectors within biotechnology. With the 4 pending office actions and the distinct examiners, the company faces multiple reviews. Practitioners should note that Dent, Alana Harris handles 2 pending office actions, making her a central figure for the active portfolio. The alignment of the pending office actions across the art units indicates the administrative footprint for the company's current filings in the Biotechnology & Pharmaceuticals area. This structure requires coordination across the different administrative divisions.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DENT, ALANA HARRIS | 2 | 44.2% | +32.0% |
| TAYLOR, LIA ELAN | 1 | 64.4% | +29.4% |
| BERHANE, SELAM | 1 | 58.4% | +56.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18645607 | Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases | DENT, ALANA HARRIS | 60d overdue |
| 18644720 | METHODS AND COMPOSITIONS FOR MODIFYING MACROPHAGE POLARIZATION INTO PRO-INFLAMMATORY CELLS TO TREAT CANCER | TAYLOR, LIA ELAN | 38d overdue |
| 18463454 | Anti-CD28 Humanized Antibodies Formulated for Administration to Humans | DENT, ALANA HARRIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18645607 | Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases | DENT, ALANA HARRIS | 60d overdue |
| 18644720 | METHODS AND COMPOSITIONS FOR MODIFYING MACROPHAGE POLARIZATION INTO PRO-INFLAMMATORY CELLS TO TREAT CANCER | TAYLOR, LIA ELAN | 38d overdue |
| 18463454 | Anti-CD28 Humanized Antibodies Formulated for Administration to Humans | DENT, ALANA HARRIS | — |
| 18060129 | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent | BERHANE, SELAM | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1641 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18645607 | Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases | DENT, ALANA HARRIS | 1643 | §102§103§112 | Final Rejection | 60d overdue | Pending | Apr 25, 2024 |
| 18644720 | METHODS AND COMPOSITIONS FOR MODIFYING MACROPHAGE POLARIZATION INTO PRO-INFLAMMATORY CELLS TO TREAT CANCER | TAYLOR, LIA ELAN | 1641 | §103§112 | Final Rejection | 38d overdue | Pending | Apr 24, 2024 |
| 18463454 | Anti-CD28 Humanized Antibodies Formulated for Administration to Humans | DENT, ALANA HARRIS | 1643 | §102§103 | Final Rejection | — | Pending | Sep 08, 2023 |
| 18060129 | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent | BERHANE, SELAM | 1675 | §102§103DP | Non-Final OA | — | Pending | Nov 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial